Protocol
Soy protein for LDL cholesterol
In 41 trials analyzed for LDL Low-density lipoprotein cholesterol, the cholesterol fraction most closely tied to plaque in the arteries. from the 46 the FDA reviewed (median 25 g a day for 6 weeks), soy protein lowered LDL cholesterol by 4.76 mg/dL, about 3 to 4 percent.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
At a glance
Soy protein comes from foods like tofu, soy milk and edamame. In the trials the FDA reviewed, it lowered LDL cholesterol by about 5 points. That is a small drop, below the size EBL needs for a B. Most single trials were too small to show it alone. The letter is C.
- What was measured
- LDL cholesterol after weeks to months on the diet.
- How big
- LDL cholesterol was 4.76 mg/dL lower with soy protein.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 31006811.
- Who it applies to
- Adults with raised LDL over about 6 weeks.
- Safety
- None specific identified in the trials pooled.
- Compared with
- Non-soy protein, usually dairy or other animal protein.
- Certainty
- Grade C, resting on: Meta-analysis A study that pools the numbers from several trials into one combined estimate. of 41 randomized trials.
- What would change this grade
- Could rise to B with: Randomized trial. Who: Adults with raised LDL. Measured: LDL cholesterol and cardiovascular events. Length: At least 6 months.
- Cost
- No price recorded yet.
- Sources
- 2 studies cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
In 41 trials analyzed for LDL from the 46 the FDA reviewed (median 25 g a day for 6 weeks), soy protein lowered LDL cholesterol by 4.76 mg/dL, about 3 to 4 percent. The effect is below EBL's 0.20 mmol/L (7.7 mg/dL) threshold for a B on LDL, so the letter is C.
Why this letter
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on LDL cholesterol. A meta-analysis of the FDA's 46 trials found LDL 4.76 mg/dL lower (Blanco Mejia et al., 2019; PMID 31006811).
WHY NOT Bbelow the magnitude threshold. Under EBL's LDL rule (November 2026), a B on LDL needs a pooled between-group change of at least 0.20 mmol/L (about 7.7 mg/dL) with a confidence interval The range the true effect probably falls in. A wide interval means the estimate is uncertain. excluding no effect; this is an EBL operating threshold taken from the lower bound of the published 'moderate' category (Schoeneck et al., 2021; PMID 33762150), not a validated clinical cutoff.
WHAT THIS GRADE DOES NOT COVERsoy isoflavone supplements, and heart attacks or strokes, which were not measured. It also does not cover fermented soy foods such as tempeh and miso, which the trials did not test separately.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: meta-analysis
Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: LDL cholesterol (surrogate)
Last reviewed: November 2026
The trial that would change this grade.
A positive trial of this shape, supported by further trials, would move this entry to B.
Why the current trials fall short
A larger or longer pooled effect would be needed.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Soy Proteins among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Soy Proteins on ClinicalTrials.gov
Dose, form and timing
Fasting LDL cholesterol.
Safety
No safety data. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
None recorded.
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 454 · November 2026 · First graded.
New record in the food section. In 41 trials analyzed for LDL from the 46 the FDA reviewed (median 25 g a day for 6 weeks), soy protein lowered LDL cholesterol by 4.76 mg/dL, about 3 to 4 percent. The effect is below EBL's 0.20 mmol/L (7.7 mg/dL) threshold for a B on LDL, so the letter is C.PMID 31006811 PMID 33762150
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullTwo papers, each linked to its PubMed record.
Blanco Mejia et al. (J Nutr, 2019; PMID 31006811): meta-analysis of the 46 trials identified by the FDA, 41 with LDL data; soy protein median 25 g a day for 6 weeks lowered LDL by 4.76 mg/dL (95% CI -6.71 to -2.80) against non-soy protein; most individual trials were not significant. Schoeneck et al. (2021; PMID 33762150): soy protein classed as a small LDL reduction.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
("soy protein"[tiab]) AND LDL[tiab] AND meta-analysis[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →